Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palifermin for Oral Mucositis in Colon Cancer
NCT00393822Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2005
- Primary completion
- Dec 2007
- Modality
- Cytokines & Interferons
01
Overview
Phase 3, randomised, double-blind trial of palifermin in oral mucositis (OM) (2 arms), sponsored by Amgen. Primary endpoint: Incidence of Grade ≥ 2 (WHO scale) oral mucositis at Cycle 1. Started Aug 2005; status: completed.
02
Drugs
palifermin
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT00393822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393822.